The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy.

Abstract

BACKGROUND:

We investigated the impact of the age-adjusted Charlson comorbidity index (ACCI) on the pancreatic cancer survival and recurrence after curative surgery followed by adjuvant chemotherapy.

PATIENTS AND METHODS:

This study included 155 patients who underwent curative surgery followed by adjuvant chemotherapy for pancreatic cancer between 2005 and 2014. The risk factors for the overall survival (OS) and recurrence-free survival (RFS) were identified.

RESULTS:

An ACCI of 8 was regarded as the optimum critical point of classification considering the 1-, 3- and 5-year survival rates. The OS rates at 3 and 5 years after surgery were 25.7% and 19.0% in the ACCI-low group, respectively, and 7.6% and 0% in the ACCI-high group, which amounted to a statistically significant difference (P = 0.019). The RFS rates at 3 and 5 years after surgery were 17.3% and 13.8% in the ACCI-low group, respectively, and 7.1% and 0% in the ACCI-high group, which amounted to a marginally statistically significant difference (P = 0.104). A multivariate analysis showed that the ACCI was a significant independent risk factor for both the OS and RFS.

CONCLUSIONS:

The ACCI was a risk factor for the OS in patients who underwent curative surgery followed by adjuvant chemotherapy for pancreatic cancer. An effective plan is needed for determining the optimum surgical strategy according to the ACCI.

• Authors: Toru Aoyama, Naoto Yamamoto, Mariko Kamiya, Masaaki Murakawa, Hiroshi Tamagawa, Sho Sawazaki, Masakatsu Numata, Satoshi Kobayashi, Makoto Ueno, Manabu Morimoto, Manabu Shiozawa, Norio Yukawa, Takashi Oshima, Takaki Yoshikawa, Yasushi Rino, Munetaka Masuda, Soichiro Morinaga
• Journal: Journal of cancer research and therapeutics (J Cancer Res Ther) Vol. 16 Issue Supplement Pg. S116-S121 (Dec 2020) ISSN: 1998-4138 [Electronic] India
• PMID: 33380664 (Publication Type: Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Deoxycytidine
• Gemcitabine

Topics

• Adult
• Age Factors
• Aged
• Aged, 80 and over
• Antimetabolites, Antineoplastic (therapeutic use)
• Chemotherapy, Adjuvant
• Comorbidity
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Disease-Free Survival
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local (epidemiology, prevention & control)
• Pancreatectomy
• Pancreatic Neoplasms (mortality, therapy)
• Prognosis
• Retrospective Studies
• Risk Assessment (methods, statistics & numerical data)
• Risk Factors
• Survival Rate
• Gemcitabine